P530 Ultra-proactive therapeutic drug monitoring incorporating infliximab point-of-care testing with ad hoc dose adjustment reduces C-reactive protein levels in patients with IBD during infliximab maintenance treatment
Details
The content you want is available to Zendy users.Already have an account? Click here. to sign in.